HOMERITZ CORPORATION BERHAD - WARRANTS 2
KLSE: HOMERIZ-WA (5160WA)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.005
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Overview
Type
Company Warrant
Sector
CONSUMER PRODUCTS & SERVICES
Listing Date
15-Jul-2015
Maturity Date
09-Jul-2020
Issue Size
50,000,000
Exercise Price
MYR 0.92
Ratio
1:1
Timeline
Expired!
Listing Date: 15-Jul-2015
Maturity Date: 09-Jul-2020
Prices
Warrant Price
0.00
Exercise Price
0.92
Underlying Stock Price
0.58
Conversion Ratio
1:1
Additional Info
Issuer
-
Description
Issuance of 50,000,000 free warrants in Homeritz Corporation Berhad ("HCB") ("Warrants") on the basis of one (1) Warrant for every four (4) existing ordinary shares of RM0.20 each in HCB held at 5.00 p.m. on 7 July 2015 ("Free Warrants Issue")
Discussions
3 people like this. Showing 22 of 22 comments
yesterday n today BLACK day for Bursa....what's next? Monday mild rebound?
2015-08-07 11:24
Homeriz-wa is severely undervalued and this is why investors is chasing for WA now.
Company purchased a land for which is nearby the existing production factory, clearly this land is meant for production expansion. So to look at reason production expansion is either more orders coming in and current capacity cannot cope or new contracts expected to receive and they need more production space.
in long run, warrant is good investment tools as in view of the future company expansion plan and business growing trend. Assuming share price to hit RM1.60 in Year2016, the warrant price should stand at ~RM1.00, which offers another 100% growth for investors.
2015-09-09 09:16
Looks interesting. What is the -wa details i.e. conversion, expiry etc? Thks.
2015-10-06 13:35
High premium to mother share... Is it normal because of long expire date?
2015-10-14 11:46
Beza Homeritz Corporation - FY16 Results ? Below Expectations
Author: kltrader | Publish date: Fri, 28 Oct 2016, 09:52 AM
Results
Homeritz’s 4QFY16 revenue of RM33.9m was translated into PATAMI of RM4.6m. This brought FY16 Core PATAMI to RM27.6m, accounting for 88.5% of our full year estimate.
Deviations
Lower than expected production volume and margin due to shortage of foreign labour.
Dividends
A final single tier tax-exempt dividend of 3.0 sen was declared in 4Q.
Highlights
Yoy: Homeritz’s FY16 revenue increased 8% yoy to RM157.6m mainly contributed by stronger US$ against MYR. Consequently, PATAMI improved by 19% yoy due to stronger US$ against MYR and lower leather cost despite a higher labour cost (circa 12% yoy) and a reduction in sales volume (-1% yoy).
QoQ: 4QFY16 revenue experienced a double digit contraction, recording RM33.9m (-16.2% qoq) caused by a 14.9% decline in volume sold. This is mainly attributed by the shortage in foreign manpower which has also reduced EBITDA margin by 7%-pts qoq. Consequently, PATAMI weakened to RM4.6m (-29% qoq).
Outlook: Homeritz requires skilled foreign workers to manufacture its products. However, the government’s decision to temporarily freeze the intake of foreign workers in Feb 2016 has caused a shortage in their manpower. The company has recently managed to secure the approval to hire and bring in foreign workers which will allow the company to recover its production output especially with new capacity expected to come in by next year. Thus, we expect sales volume to recover and EBITDA margin to normalize gradually in FY17.
Risks
USD weakness against RM; high raw material prices; high labour costs; unexpected economic downturn; and production or operational risks.
Forecasts
FY17-18 net profit forecasts are reduced by 3% and 1% respectively.
Rating
BUY (↔), TP: RM1.06 ↑
Despite the unexpected blip in manpower which resulted in lower volume production, we expect the company to recover its output with the recent approval to bring in foreign labour. Homeritz also benefits from recent ringgit weakness against US$.
Valuation
We maintain our BUY recommendation with a lower target price ofRM1.06 (previously RM1.09) after incorporating latest forecasts based on unchanged P/E multiple of 11x of CY17 EPS.
Source: Hong Leong Investment Bank Research - 28 Oct 2016
2016-10-28 10:44
Post a Comment
Featured Posts
Apps
Top Articles
1
2
Kenanga Research & Investment
3
4
5
https://dividendguy67.blogspot.com
7
BFM Podcast
8
PublicInvest Research
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Invest123
Well done. Thanks.
2015-07-15 21:08